Key Highlights
- Shares are up 1.89% pre-market to $2.70, building on a prior close of $2.65.
- The company completed the last patient, last visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial evaluating MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis.
- Topline results from the double-blind portion are expected by the end of 2026, with 234 participants randomized across US and Canadian sites.
MediciNova (NASDAQ:MNOV) shares are up 1.89% pre-market to $2.70, building on a prior close of $2.65, after the company announced the completion of the last patient, last visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 trial evaluating MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis. A total of 234 participants were randomized across clinical sites in the United States and Canada, with the drug designed to modulate neuroinflammation and oxidative stress pathways implicated in ALS progression.
Participants remaining in the study are continuing treatment in an open-label extension phase, with the full study's last patient visit expected in March 2027. The company said it expects to report topline results from the double-blind portion by the end of 2026. MN-166 has received Fast Track and Orphan Drug designations from the FDA, along with orphan designation from the European Medicines Agency.
How the Trial Is Designed
COMBAT-ALS is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of MN-166 over a 12-month double-blind treatment period, followed by a 6-month open-label extension. The trial's primary endpoint is a combined assessment of function and survival, while secondary endpoints include a standard ALS functional rating scale, muscle strength measured by hand-held dynamometry, and quality-of-life assessments.
A Favorable Safety History
MN-166 has demonstrated a favorable safety profile in prior Phase 1/2 and Phase 2 clinical studies, with earlier studies also showing a higher proportion of treatment responders among participants who received the drug compared to placebo. That track record has helped support the compound's continued advancement into this later-stage combined Phase 2b/3 trial design.
A Pipeline Beyond ALS
Beyond ALS, MN-166 is also in development for progressive multiple sclerosis, degenerative cervical myelopathy, glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy, and substance use disorder, giving the company multiple potential paths to a first approval built around a single compound with an established safety record.






Please wait processing your request...